News
Stockhead on MSN1h
Top 10 at 11: ASX dips in early trade; Amplia achieves second pancreatic cancer complete responseASX slips 0.16pc as tech and materials sectors lag. Amplia Therapeutics reports a second complete response in its pancreatic cancer trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback